Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
<h4>Background</h4>Clinical trials suggest that use of fixed-dose combination therapy ('polypills') can improve adherence to medication and control of risk factors of people at high risk of cardiovascular disease (CVD) compared to usual care, but cost-effectiveness is unknown.&...
Saved in:
| Main Authors: | Sue Jowett, Pelham Barton, Andrea Roalfe, Kate Fletcher, F D Richard Hobbs, Richard J McManus, Jonathan Mant |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0182625&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE ROLE OF POLYTABLETS (POLYPILL) IN THE TREATMENT OF CHRONIC CARDIOVASCULAR DISEASES
by: Николай Владимирович Абрамов, et al.
Published: (2024-02-01) -
Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trialResearch in context
by: Thomas Gaziano, et al.
Published: (2025-08-01) -
Secondary prevention of cardiovascular disease: is it time for the polypill to be standard treatment?
by: Tom Marshall
Published: (2025-08-01) -
Relevance of Polypill for Primary Prevention of Cardiovascular Diseases in the 21st Century
by: Rajeev Gupta
Published: (2025-06-01) -
Effective polypill therapy in patients with hypertension and dyslipidemia
by: V. E. Oleynikov, et al.
Published: (2025-07-01)